Prevention of Poststroke Depression After Acute Ischemic Stroke Using the Selective Serotonine Reuptake-Inhibitor Sertraline "PreDIS-Study"


Phase N/A Results N/A

Summary of Purpose

To limit adverse events (i.e., higher mortality) by the use of a selective serotonin reuptake inhibitor for which safety, tolerability, and efficacy has been shown in depressive patients with stroke or myocardial infarction.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 27 May 2009.

Unavailable Unavailable Unavailable Unavailable Unavailable Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics



  • Pfizer Inc

Trial Design

Double-blind, randomized, placebo-controlled trial.


  • PD Dr M. Sitzer, Zentrum der Neurologie und Neurochirurgie, J.W. Goethe-Universitat Frankfurt/Main, Schleusenweg 2-16, D-60528 Frankfurt/Main, Germany. Phone 49-6301-5942. Fax 49-6301-4498. E-mail